Erratum: Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the kathleen cuningham foundation consortium for research into familial breast cancer (kConFab) (Breast Cancer Res Treat (2010) (120) DOI: 10.1007/s10549-009-0497-8));Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 715-723

  Kiely, Belinda E ^a   Jenkins, Mark A ^b   McKinley, Joanne M ^a   Friedlander, Michael L ^c   Milne, Roger L ^b,d   McLachlan, Sue Anne ^b,e   Hopper, John L ^b   Phillips, Kelly Anne ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d Centro Nacional de Investigations Oncológicas   (Spain)

^e ST VINCENT S HOSPITAL   (Australia)

Author keywords

BRCA1 2; Breast cancer; Contralateral prophylactic mastectomy; Familial breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL ASSESSMENT; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MUTATIONAL ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; SALPINGOOOPHORECTOMY;

EID: 77950862424     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0528-5     Document Type: Erratum

References (21)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717 (Pubitemid 40719106)
2. Harris RE, Lynch HT, Guirgis HA (1978) Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 60: 955-960 (Pubitemid 8335934)
3. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade Ol, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22: 2328-2335 (Pubitemid 41115389)
4. van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93: 287-292
5. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19: 3938-3943
6. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122: 2017-2022
7. Phillips KA, Jenkins MA, Lindeman GJ, McLachlan SA, McKinley JM, Weideman PC, Hopper JL, Friedlander ML (2006) Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 70: 198-206
8. Dawson SJ, Price MA, Jenkins MA, McKinley JM, Butow PN, McLachlan SA, Lindeman GJ, Weideman P, Friedlander ML, Hopper JL, Phillips KA (2008) Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham foundation consortium for research into familial breast cancer. J Clin Oncol. 26: 225-232
9. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Moller P, Weitzel J, Sun P, Narod SA (2008) Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26: 1093-1097
10. Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD (2007) Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat 104: 321-329 (Pubitemid 47231279)
11. Turtle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25: 5203-5209
12. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22: 1823-1829 (Pubitemid 41095172)
13. Kathleen Cunningham Consortium for Research into Familial Breast Cancer: kConFab.
14. Mann GJ, Thome H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8: R12
15. Phillips KA, Butow PN, Stewart AE, Chang JH, Weideman PC, Price MA, McLachlan SA, Lindeman GJ, McKay MJ, Friedlander ML, Hopper JL (2005) Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Fam Cancer 4: 105-113
16. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D (2004) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6: R375-R389
17. Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, Giles GG, Hopper JL (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol 23: 4679-4686 (Pubitemid 46224070)
18. Evans DG, Lalloo F, Hopwood P, Maurice A, Baildam A, Brain A, Barr L, Howell A (2005) Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 31: 1112-1118 (Pubitemid 41819194)
19. McKinley JM (2008) Risk-reducing surgery in BRCA1 and BRCA2 mutation carriers: an update. Proceedings of the Familial Cancer Research and Practice Meeting; August 19-22; Couran Cove, Australia
20. Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 4: CD002748
21. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23: 4275-4286 (Pubitemid 46207002)